Sources and sharing

BCTX - BriaCell Therapeutics Corp. Noncurrent Liabilities

Context
Latest reported period: Q1 2022
Latest reported value
$278,396

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.

Tracking and update notes

Why revisit this metric view

This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.

Latest source-backed update
Latest period end 30 Apr 2022
Why come back
Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
  • Current latest reported period: Q1 2022.
  • Latest reported value on this page: $278,396.
  • Save this filer if you want to compare the next reported value with this history.

Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.

Latest update

Latest update for Noncurrent Liabilities

New fact period available

Latest reported noncurrent liabilities: $278,396. Open the source-backed page to compare this metric with the newest filing-backed context.

Update date

30 Apr 2022

Page type

Metric history

Latest period

Q1 2022

SEC-backed company facts were refreshed from filings filed on 28 Oct 2026.

Benchmark Context

How Noncurrent Liabilities compares with peers

BriaCell Therapeutics Corp. sits in the bottom quarter of the current noncurrent liabilities sample.

Compared with

Compared with 42 companies reporting noncurrent liabilities in USD. This keeps the comparison on the same metric and unit family.

Why this is notable

This is about 0x the current sample midpoint. Noncurrent Liabilities does not yet have enough prior-period data for a historical comparison on this page.

  • Visible rows currently span reported period ends from 31 Dec 2017 to 30 Sep 2025.
  • Nearby companies in this sample: VCI Global Ltd and Entera Bio Ltd..
  • Current sample position: rank #38 of 42 comparable companies.
  • Peer rows use the latest valid value per company for this exact metric and compatible units.

Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.

Financial Metric Page

BriaCell Therapeutics Corp.: Noncurrent Liabilities

Latest period: Q1 2022. Period end: 30 Apr 2022. Units: USD and CAD. Frequency: quarterly.

Noncurrent Liabilities is reported in company XBRL facts filed with the SEC.

What this metric tells you

  • Shows reported noncurrent liabilities over 31 Jul 2020 - 30 Apr 2022.
  • Use consecutive periods in the table to assess trend direction when YoY change is unavailable.
  • Built from 5 SEC fact rows for this metric and issuer.

How to read this chart

  • Start with the latest point, then compare it with the prior periods to see direction.
  • Use quarterly sequence to compare like-for-like periods.
  • Use YoY change bars to separate growth from contraction across matching periods.

Compare This Metric Across Companies

Compare latest available Noncurrent Liabilities levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.

BriaCell Therapeutics Corp. appears at rank #38 in the latest comparison sample.

Rank Company Latest value Report period Next step
1 CRH PUBLIC LTD CO (crh) $13,962,000,000 Instant - 31 Dec 2022 Open CRH PUBLIC LTD CO Noncurrent Liabilities
2 Flutter Entertainment plc (flut) $5,605,445,000 Instant - 31 Dec 2019 Open Flutter Entertainment plc Noncurrent Liabilities
3 Diversified Energy Co (dec) $4,028,738,000 Instant - 30 Jun 2025 Open Diversified Energy Co Noncurrent Liabilities
4 Atlassian Corp (team) $1,431,547,000 Instant - 30 Jun 2022 Open Atlassian Corp Noncurrent Liabilities
5 Orion S.A. (oec) $767,972,000 Instant - 30 Sep 2018 Open Orion S.A. Noncurrent Liabilities
6 Indivior Pharmaceuticals, Inc. (indv) $649,000,000 Instant - 31 Dec 2023 Open Indivior Pharmaceuticals, Inc. Noncurrent Liabilities

Metric Details

Metric identity Names, identifiers, and filing context for this profile. 1 identity field
Taxonomy
ifrs-full
Metric coverage 3 source fields
Units tracked
USD and CAD
History range
31 Jul 2020 - 30 Apr 2022
Freshness: From parsed SEC XBRL facts on this page
Facts on this page
5
Source: SEC company facts API
Source evidence Original filing metadata and source links for verification. 1 source field
SEC metric endpoint
Open SEC company concept

Chart Context

Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.

Noncurrent Liabilities, Quarterly (USD)
Noncurrent Liabilities, YoY Quarterly Change (%)
Noncurrent Liabilities, Quarterly (CAD)

BriaCell Therapeutics Corp. Quarterly Noncurrent Liabilities (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2022 $278,396 30 Apr 2022 6-K 13 Jun 2022 2022 Q3
Q4 2021 $248,486 31 Jan 2022 6-K 15 Mar 2022 2022 Q2
Q2 2021 $225,444 +$69,504 +45% 31 Jul 2021 6-K 13 Jun 2022 2022 Q3
Q2 2020 $155,940 31 Jul 2020 40-F/A 16 Nov 2021 2021 FY

BriaCell Therapeutics Corp. Quarterly Noncurrent Liabilities (CAD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2020 CA$191,572 31 Jul 2020 40-F/A 16 Nov 2021 2021 FY
* marks a reported value that did not pass the local value check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .